Full-year revenue guidance now at the higher end of the previous range, Adjusted EBITDA guidance up BARCELONA, Spain, Nov. 25, 2024 /PRNewswire/ -- Freightos Limited ...
TORONTO, ON / ACCESSWIRE / November 25, 2024 / Northern Superior Resources Inc. ("Northern Superior") (TSXV:SUP)(OTCQX:NSUPF)(GR:D9M1) is pleased to announce that ONGold Resources Ltd. ("ONGold" or th ...
Global Technologies, Ltd (OTC: GTLL), a multi-operational company driving innovation and sustainable growth across the technology and service sectors ...
Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge" or the "Company") announced today that the Tsetsaut Skii km Lax Ha ("TSKLH") has filed a ...
Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton's existing pediatric endocrinology focusAmglidia has been grant ...
Achieves quarterly revenues of $7.2 million at top-end of guidance, record net profit of $4.2 million and Adjusted EBITDA outperformed guidance at $1.4 million; strong cash generation and $24.0 millio ...
U-BX Technology Ltd. (the "Company" or "U-BX") (NASDAQ:UBXG), a leading company providing value-added services using artificial intelligence-driven technology ...
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA ...
BUENOS AIRES, ARGENTINA / ACCESSWIRE / November 25, 2024 / NOA Lithium Brines Inc. (TSX-V:NOAL)(FSE:N7N) (" NOA " or the " Company ") is pleased to provide an update on the significant progress of its ...
Global Crossing Airlines Group, Inc. (Cboe CA: JET, Cboe CA: JET.B, OTCQB: JETMF) (the "Company" or "GlobalX"), the Nation's fastest growing charter airline, ...
Cenovus Energy Inc. ("Cenovus" or the "Company") (TSX: CVE) (NYSE: CVE) announced today it will exercise its right to redeem the Company's 4.689% Series ...
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study Simufilam contin ...